Search

Displaying results 8431 - 8440 of 10000 in total
  1. Drug

    Topramezone

    go.drugbank.com/drugs/DB14826
    Experimental

    Topramezone is under investigation in clinical trial NCT00559520 (The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery).

  2. Drug

    Telisotuzumab

    go.drugbank.com/drugs/DB14838
    Investigational

    Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).

  3. Drug

    TBA-7371

    go.drugbank.com/drugs/DB16243
    Investigational

    TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis).

  4. Drug

    STG-001

    go.drugbank.com/drugs/DB16734
    Investigational

    STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt Disease).

  5. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  6. Drug

    Allopurinol riboside

    go.drugbank.com/drugs/DB17738
    Experimental

    Allopurinol riboside is a nucleoside analogue of [allopurinol] with a beta-D-ribofuranosyl moiety at the 1-position.

  7. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]

  8. Drug

    DengueCide

    go.drugbank.com/drugs/DB18546
    Experimental

    DengueCide is a nonjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer

  9. Drug

    Zigakibart

    go.drugbank.com/drugs/DB18892
    Investigational

    Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).

  10. Drug

    Supinoxin

    go.drugbank.com/drugs/DB19010
    Investigational

    Supinoxin is under investigation in clinical trial NCT02003092 (RX-5902 Treatment of Subjects With Triple Negative Breast Cancer).